TY - JOUR
T1 - Leaf Effect of C. Trifolia L. as Nf-B and Tnf-Α Inhibitor Compounds with In Silico Method
AU - Sukmana, Judya
AU - Widjiati,
AU - Siswandono,
AU - Sudiana, I. Ketut
AU - Notobroto, Hari Basuki
AU - Saputro, Iswinarno Doso
AU - Dachlan, Yoes Prijatna
AU - Joewarini, Endang
N1 - Publisher Copyright:
© 2022 EManuscript Technologies. All rights reserved.
PY - 2022/7
Y1 - 2022/7
N2 - Introduction: Infection H. pylori causes inflammation through various pathways to induce pro-inflammatory cytokines such as IL-1, IL-6, IL-8, and TNF-α. The transcription factor NF-kB is a crucial regulator of the immune response and inflammation and regulates many cellular processes that are important in carcinogenesis, including transformation, proliferation, angiogenesis, and metastasis. Anti-inflammatory plant C. trifolia L was shown to inhibit the activity of NF-B and several pro-inflammatory cytokine mediators. This study proved that the active compound from the plant's leaves, C. trifolia L has potential as an inhibitor of NF-B and TNF-α. Method: This study used a docking method with a grid box mimicking the bond between the receptor and the inhibitor control complex. Results: The bioactivity of Cayratria trifolia compounds as anti-inflammatory was shown in the inflammation parameters used, namely Interleukin 10 agonist, Interleukin agonist, Interleukin antagonist, Interleukin 6 antagonist, Interleukin 4 antagonist, Interleukin 2 agonist, Interleukin 1 antagonist, Interleukin 1b antagonist, Interleukin 10 antagonist, Interleukin 12 agonist, and Interleukin 1a antagonist. Interleukin 2 agonists showed the highest activity of all compounds. Piceid compounds showed high anti-inflammatory activity with interleukin 10 agonists, interleukin agonists, interleukin 6 antagonists, and interleukin 2 agonists. The compounds stilbenes, piceid, resveratrol, cyclopentadecane, and hentriacontane showed potency higher interleukin-6 inhibition than the other 22 compounds. These five compounds were continued for molecular docking analysis. The low bond energy is correlated with the number of bonds and the variety of interactions. The higher the number of bonds and the type of interaction, the lower the bond energy. The lower the bond energy, the stronger the interaction between the ligand and protein. Conclusion: Based on the prediction of anti-inflammatory bioactivity, five potential compounds were identified, namely cyclopentadecane, resveratrol, stilbenes, piceid, and hentriacontane. The five compounds bind to NFkB on the active site of the binding site with DNA, and this inhibition causes DNA to be unable to restrain NFkB transcription factors, and transcription does not occur. This proves that the active compound from the leaves of the plant C. trifolia L has potential as an inhibitor of NF-κB compounds. Inhibition of 6 compounds on TNF at the TNF receptor proves that the active compound from the leaves of the plant C. trifolia L has potential as a TNF-α inhibitor compound. The active ingredient Piceid exhibits predominant anti-inflammatory potential with lower binding energy and stronger interactions than other complexes.
AB - Introduction: Infection H. pylori causes inflammation through various pathways to induce pro-inflammatory cytokines such as IL-1, IL-6, IL-8, and TNF-α. The transcription factor NF-kB is a crucial regulator of the immune response and inflammation and regulates many cellular processes that are important in carcinogenesis, including transformation, proliferation, angiogenesis, and metastasis. Anti-inflammatory plant C. trifolia L was shown to inhibit the activity of NF-B and several pro-inflammatory cytokine mediators. This study proved that the active compound from the plant's leaves, C. trifolia L has potential as an inhibitor of NF-B and TNF-α. Method: This study used a docking method with a grid box mimicking the bond between the receptor and the inhibitor control complex. Results: The bioactivity of Cayratria trifolia compounds as anti-inflammatory was shown in the inflammation parameters used, namely Interleukin 10 agonist, Interleukin agonist, Interleukin antagonist, Interleukin 6 antagonist, Interleukin 4 antagonist, Interleukin 2 agonist, Interleukin 1 antagonist, Interleukin 1b antagonist, Interleukin 10 antagonist, Interleukin 12 agonist, and Interleukin 1a antagonist. Interleukin 2 agonists showed the highest activity of all compounds. Piceid compounds showed high anti-inflammatory activity with interleukin 10 agonists, interleukin agonists, interleukin 6 antagonists, and interleukin 2 agonists. The compounds stilbenes, piceid, resveratrol, cyclopentadecane, and hentriacontane showed potency higher interleukin-6 inhibition than the other 22 compounds. These five compounds were continued for molecular docking analysis. The low bond energy is correlated with the number of bonds and the variety of interactions. The higher the number of bonds and the type of interaction, the lower the bond energy. The lower the bond energy, the stronger the interaction between the ligand and protein. Conclusion: Based on the prediction of anti-inflammatory bioactivity, five potential compounds were identified, namely cyclopentadecane, resveratrol, stilbenes, piceid, and hentriacontane. The five compounds bind to NFkB on the active site of the binding site with DNA, and this inhibition causes DNA to be unable to restrain NFkB transcription factors, and transcription does not occur. This proves that the active compound from the leaves of the plant C. trifolia L has potential as an inhibitor of NF-κB compounds. Inhibition of 6 compounds on TNF at the TNF receptor proves that the active compound from the leaves of the plant C. trifolia L has potential as a TNF-α inhibitor compound. The active ingredient Piceid exhibits predominant anti-inflammatory potential with lower binding energy and stronger interactions than other complexes.
KW - C. trifolia L
KW - H. Pylori
KW - In silico
KW - NFkB
KW - TNF-α
UR - http://www.scopus.com/inward/record.url?scp=85137718064&partnerID=8YFLogxK
U2 - 10.5530/pj.2022.14.115
DO - 10.5530/pj.2022.14.115
M3 - Article
AN - SCOPUS:85137718064
SN - 0975-3575
VL - 14
SP - 407
EP - 415
JO - Pharmacognosy Journal
JF - Pharmacognosy Journal
IS - 4
ER -